Advanced searches left 3/3

Sofosbuvir, Velpatasvir, And Voxilaprevir - Europe PMC

Summarized by Plex Scholar
Last Updated: 12 July 2022

* If you want to update the article please login/register

Effectiveness and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir as a Hepatitis C Virus Infection Salvage Therapy in the Real World: A Systematic Review and Meta-analysis.

Introduction Sofosbuvir/Velpatasvir/Voxilaprevir is the first direct-acting antiviral therapy approved for patients who have previously failed a DAA-containing regimen, which includes NS5A inhibitors. Conclusions Fifteen studies with a total of 1796 HCV-infected patients with previous treatment failure were included in this series. SVR12 rates in the ITT populations and 96% in the PP populations were 93% and 96% respectively. In non-GT3-infected patients and non-cirrhotic patients, the incidence of SVR12 in non-infected patients and non-cirrhotic patients was much higher than in GT3-infected patients and cirrhotic patients than in cirrhotic patients and cirrhotic patients. In addition, the SVR12 rates of previous SOF/VEL treatment were much lower than those of other modalities in both ITT and PP populations. Conclusions are consistent with clinical findings, the objective world evidence shows that SOF/VEL/VOX is a well-tolerated and highly effective recovery therapy for HCV-infected patients with previous treatment failure. However, there may still be a chance of treatment failure for patients with GT3 infection, cirrhosis, or SOF/VEL treatment failure.

Source link: https://europepmc.org/article/MED/35749010

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions